AMACR targeted drugs for treating advanced prostate cancer

In a nutshell

The researchers aim to discover new drugs to specifically block the function of a protein called AMACR, which is involved in prostate cancer growth, as a new treatment for advanced prostate cancer.

Why we funded it

We know that a protein called AMACR is somehow involved in prostate cancer development. When AMACR function levels are lowered, prostate cancer cell growth is also reduced. This makes it an exciting drug target, but until now, it has been difficult to measure AMACR function. In a previous Prostate Cancer UK PhD studentship, the researchers found a way to get around this.

This grant will allow the researchers to build on this work, first to refine their AMACR function assay, and then to look for new drugs that will stop the protein working and help in the development of new treatments for advanced prostate cancer.

Grant information

Researcher - Dr Matthew David Lloyd
Institution - University of Bath
Grant award - £278,037.00
Reference - PG14-009